Switch to
Predicate | Object |
---|---|
rdf:type | |
lifeskim:mentions | |
pubmed:issue |
1
|
pubmed:dateCreated |
1999-2-3
|
pubmed:abstractText |
The natural history of hepatitis C virus (HCV) infection following liver transplantation and predictors of disease severity remain controversial. The aims of the study were to assess in a homogeneous population of 81 cyclosporine-based HCV-infected liver transplant recipients mostly infected with genotype 1b and undergoing strict protocol annual biopsies: 1) the histological progression of posttransplantation HCV disease and, in particular, the incidence of HCV-related graft cirrhosis within the first 5 years after surgery; and 2) the relationship between progression to cirrhosis and i) rejection episodes and ii) first-year liver biopsy findings. We studied 81 consecutive HCV-RNA-positive patients (96% genotype 1b) undergoing liver transplantation between 1991 and 1996 with a minimum histological follow-up of 1 year. All patients received cyclosporine-based immunosuppression and underwent protocol yearly liver biopsies for the first 5 years. The mean histological follow-up was 32 months (range, 12-60 months). Biopsies were scored according to the histological activity index (HAI), with separate evaluation of grade (activity) and stage (fibrosis). Histological hepatitis, present in 97% of patients in the most recent biopsy, was moderate or severe in 64%. Twelve patients developed HCV-related cirrhosis at a median time of 24 months (range, 12-48 months), with an actuarial rate of HCV-cirrhosis of 3.7%, 8.5%, 16%, 28%, and 28% at 1, 2, 3, 4, and 5 years, respectively. Rejection was significantly more common among patients with cirrhosis versus those without (83% vs. 48%; P =.02), with an association between the incidence of cirrhosis and the number of rejection episodes: 5%, 15%, and 50% in patients without rejection, one and two episodes, respectively (P =.001). The degree of activity and fibrosis score in the first-year biopsy were higher in patients who developed cirrhosis than in those who did not (P =.008 and.18, respectively). In conclusion, HCV genotype 1b-infected liver recipients are at a high risk of developing graft cirrhosis in the first 4 to 5 years following transplantation, especially those with previous rejection episodes. First-year liver biopsies may help to sooner identify patients at the highest risk, improving further patient management.
|
pubmed:language |
eng
|
pubmed:journal | |
pubmed:citationSubset |
IM
|
pubmed:chemical | |
pubmed:status |
MEDLINE
|
pubmed:month |
Jan
|
pubmed:issn |
0270-9139
|
pubmed:author |
pubmed-author:ArgüelloLL,
pubmed-author:BerenguerJJ,
pubmed-author:BerenguerMM,
pubmed-author:CórdobaJJ,
pubmed-author:CarrascoDD,
pubmed-author:De JuanMM,
pubmed-author:García-HerolaAA,
pubmed-author:GobernadoMM,
pubmed-author:MirJJ,
pubmed-author:OlasoVV,
pubmed-author:PrietoMM,
pubmed-author:RayónJ MJM
|
pubmed:issnType |
Print
|
pubmed:volume |
29
|
pubmed:owner |
NLM
|
pubmed:authorsComplete |
Y
|
pubmed:pagination |
250-6
|
pubmed:dateRevised |
2004-11-17
|
pubmed:meshHeading |
pubmed-meshheading:9862874-Adult,
pubmed-meshheading:9862874-Alanine Transaminase,
pubmed-meshheading:9862874-Female,
pubmed-meshheading:9862874-Genotype,
pubmed-meshheading:9862874-Graft Rejection,
pubmed-meshheading:9862874-Hepacivirus,
pubmed-meshheading:9862874-Hepatitis C,
pubmed-meshheading:9862874-Humans,
pubmed-meshheading:9862874-Immunosuppressive Agents,
pubmed-meshheading:9862874-Liver Cirrhosis,
pubmed-meshheading:9862874-Liver Function Tests,
pubmed-meshheading:9862874-Liver Transplantation,
pubmed-meshheading:9862874-Male,
pubmed-meshheading:9862874-Middle Aged,
pubmed-meshheading:9862874-RNA, Viral,
pubmed-meshheading:9862874-Survival Analysis
|
pubmed:year |
1999
|
pubmed:articleTitle |
High incidence of allograft cirrhosis in hepatitis C virus genotype 1b infection following transplantation: relationship with rejection episodes.
|
pubmed:affiliation |
Hepatogastroenterology Service, Hospital Universitario La Fe, Valencia, Spain.mprieto@iname.com
|
pubmed:publicationType |
Journal Article,
Clinical Trial
|